Authors
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Future-Ready Leadership: Redefining the Biopharma C-suite for an AI-Driven EraHow will the tasks of C-suite leaders be transformed by intelligent technologies?
Latest:
How MSLs Can Enrich Scientific Exchange with Customer InsightIn today‘s environment, medical science liaisons (MSLs) must call on digital solutions to make use of the right data and encourage the right conversations to take place.
Latest:
What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug DevelopmentIndustry has shown it can overcome challenges en route to creating new therapies.
Latest:
How Prescribing Power Has Shifted Beyond PhysiciansNurse practitioners and physician associates are two of the fastest growing clinician groups.
Latest:
Improving Readiness for Volume-Based Procurement in ChinaVolume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
Latest:
Building Crisis Management and Risk Mitigation Plans into Patient Support ProgramsIn simple terms, patient support programs help get medicines into the hands of people who need them.
Latest:
A Biosimilars Roadmap: Understanding Payer PerceptionsWith competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
Key Considerations for Senior Executives Related to Quality CultureExploring practical points to further understand and strengthen quality culture.
Latest:
Understanding the HCP: Patient-Level Data Proves ValuableEvaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
Latest:
Embracing Generative AI: Why Its Disruption is Positive for PharmaThe new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
The American Rescue Plan Act of 2021: Pharmaceutical Industry ImpactAssessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.
Latest:
Billing Codes for DTx Would Open the Floodgates for Behavioral Health EquityApproval of Medicare and Medicaid coverage for digital therapeutics represents next step in advancing care for mental health patients.
Latest:
Emergency Use Authorization: What We’ve Learned Bringing COVID-19 Therapies to MarketPandemic forces pharma companies to work faster and smarter to meet hard deadlines.
Latest:
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based ProductsAs the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
Transforming Healthcare Data to Precision MedicineA modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.
Latest:
Empathy: The Foundation of Health LiteracyGoing beyond the words of healthcare communication.
Latest:
Not Just Another Tactic: Why Pharmaceutical Brands Need to Build a Strategy Around Point of Care MessagingPoint of care messaging offers unique advantages in pharmaceutical marketing and should be a high priority in brand strategy discussions.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
Delivery and Disruption: Navigating a Changing Care TerrainThe diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Latest:
Staying the Course: Double Down on Launch AgilityIn today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Latest:
China’s 2022 NRDL OutlookThe 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
